Voyager Therapeutics’ (VYGR) “Neutral” Rating Reiterated at Chardan Capital

Share on StockTwits

Chardan Capital reissued their neutral rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research report released on Thursday morning.

Other analysts have also issued reports about the stock. HC Wainwright set a $25.00 target price on shares of Voyager Therapeutics and gave the company a buy rating in a research report on Friday, November 30th. Zacks Investment Research upgraded shares of Voyager Therapeutics from a hold rating to a buy rating and set a $13.00 target price on the stock in a report on Saturday, November 17th. ValuEngine lowered shares of Voyager Therapeutics from a strong-buy rating to a buy rating in a research report on Monday, September 17th. BidaskClub raised shares of Voyager Therapeutics from a sell rating to a hold rating in a report on Saturday, September 29th. Finally, Morgan Stanley set a $13.00 price target on shares of Voyager Therapeutics and gave the company a hold rating in a research note on Thursday, November 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $25.56.

NASDAQ:VYGR opened at $9.10 on Thursday. Voyager Therapeutics has a 52 week low of $8.30 and a 52 week high of $31.91. The stock has a market capitalization of $307.99 million, a price-to-earnings ratio of -3.45 and a beta of 2.73.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Wednesday, November 7th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.15. The company had revenue of $2.09 million for the quarter, compared to analysts’ expectations of $3.02 million. Voyager Therapeutics had a negative net margin of 648.40% and a negative return on equity of 81.63%. As a group, equities research analysts forecast that Voyager Therapeutics will post -2.74 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the business. Rhumbline Advisers boosted its position in Voyager Therapeutics by 18.3% in the 2nd quarter. Rhumbline Advisers now owns 20,258 shares of the company’s stock valued at $396,000 after buying an additional 3,132 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in shares of Voyager Therapeutics by 17.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 101,576 shares of the company’s stock worth $1,985,000 after acquiring an additional 14,849 shares during the period. Swiss National Bank raised its position in shares of Voyager Therapeutics by 20.1% in the second quarter. Swiss National Bank now owns 35,300 shares of the company’s stock valued at $690,000 after buying an additional 5,900 shares in the last quarter. GSA Capital Partners LLP acquired a new stake in shares of Voyager Therapeutics in the second quarter valued at approximately $594,000. Finally, BlackRock Inc. raised its position in Voyager Therapeutics by 28.3% during the second quarter. BlackRock Inc. now owns 1,845,706 shares of the company’s stock valued at $36,066,000 after purchasing an additional 407,677 shares in the last quarter. 88.57% of the stock is owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Featured Story: How is Preferred Stock Different from Common Stock?

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Seren Capital, Ltd. Sells 150,000 Shares of RealPage Inc  Stock
Seren Capital, Ltd. Sells 150,000 Shares of RealPage Inc Stock
TransDigm Group Incorporated  Holdings Decreased by AQR Capital Management LLC
TransDigm Group Incorporated Holdings Decreased by AQR Capital Management LLC
Analysts Set Expectations for NIPPON STL & SU/S’s FY2019 Earnings
Analysts Set Expectations for NIPPON STL & SU/S’s FY2019 Earnings
Absolute Software  Rating Lowered to Hold at Zacks Investment Research
Absolute Software Rating Lowered to Hold at Zacks Investment Research
NextSource Materials  Price Target Cut to C$0.30 by Analysts at Eight Capital
NextSource Materials Price Target Cut to C$0.30 by Analysts at Eight Capital
BK IRELAND GRP/ADR  Stock Rating Upgraded by Berenberg Bank
BK IRELAND GRP/ADR Stock Rating Upgraded by Berenberg Bank


Leave a Reply

© 2006-2019 Ticker Report